APS Biogroup Warned On Parent Firm’s Children’s DiaResQ Misbranding
This article was originally published in The Rose Sheet
An FDA warning letter says during an inspection at Phoenix firm APS Biogroup’s facility in February, ORA Denver district officials found violative claims in addition to branding problems.
You may also be interested in...
UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.